NCT04542681View on ClinicalTrials.gov

MANP in African Americans With Hypertension

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2018

Primary Completion Date

December 30, 2022

Study Completion Date

June 30, 2023

Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
DRUG

Placebo - 1st Cycle

Subjects will receive a single SQ injection of placebo/normal saline

DRUG

MANP - 1st Cycle

Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg

DRUG

MANP - 2nd Cycle

Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER